Amit G. Singal, MD, MS discusses the case of a 60-year-old man with intermediate/advanced unresectable hepatocellular carcinoma that requires careful treatment planning because of his age, disease stage, and potential therapeutic approaches, including systemic therapies and locoregional interventions.
EP. 1: Unresectable HCC with Post-TACE Progression
February 27th 2025The panelist discusses the case of a 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC). The patient has a history of metabolic dysfunction-associated steatohepatitis managed with lifestyle changes and medication. Initially, there was no clinical or radiographic evidence of cirrhosis. The patient recently presented to his gastroenterologist complaining of abdominal pain in the upper right quadrant and fatigue.
Watch
EP. 2: Initial Treatment Options for Liver-Confined Unresectable HCC
February 27th 2025The panelist discusses first-line options including atezolizumab plus bevacizumab, lenvatinib, and sorafenib. Second-line treatments include regorafenib, cabozantinib, and ramucirumab. Clinical trials should be prioritized when available.
Watch